Trial Information

Carcinoma cervix is the 2nd most common malignancy among females and about 86% of this
burden occurs in developing countries. India accounts for 27% of world cervical cancer
burden; and most of them are of locally advanced stage ie stage IIA to IVA.

Significant development in radiation techniques and addition of cisplatin based chemotherapy
to radiation schedule has led to improved survival but still it is far from satisfactory
with 20 to 25% patients failing locally while 10 to 20% patients fail at distant sites.
Novel techniques are required to improve this dismal rate.

Thus investigators intended to use combination chemotherapy with paclitaxel and cisplatin,
considering that paclitaxel is a taxane which has shown good efficacy in other solid tumors
such as ovary, lung and breast; it has also shown radiosensitizing effect in cervical cancer
cell lines and it has also been shown to be effective in phase III trials with cisplatin in
metastatic and recurrent carcinoma cervix.